Eilaf Distributing Saladax's My5-FU Test in Egypt, Other Parts of Middle East | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Saladax Biomedical said today that Eilaf Pharma will exclusively distribute the My5-FU diagnostic test in Egypt and the Middle East North African region.

Saladax's test allows physicians to determine optimal dosing of the 5-fluorouracil (5-FU) anti-cancer drug for patients, and is the first of the Bethlehem, Penn.-based firm's dose management tests to be commercially available.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.